Company news

Gilead Sciences, Inc. news in 2025

Gilead Sciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

December 24, 2025

Gilead Sciences to Present at Upcoming Investor Conference

December 21, 2025

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 21, 2025

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

December 18, 2025

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

December 17, 2025

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

December 14, 2025

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

December 8, 2025

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

December 6, 2025

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 5, 2025

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 5, 2025

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

November 23, 2025

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

November 17, 2025

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

November 12, 2025

Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

November 6, 2025

Gilead Provides Update on Phase 3 ASCENT-07 Study

November 6, 2025

Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases

November 6, 2025

Gilead Sciences to Present at Upcoming Investor Conferences

November 3, 2025

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

November 2, 2025

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

October 30, 2025

Gilead Sciences Announces Third Quarter 2025 Financial Results

October 29, 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

October 22, 2025

LYVDELZI® (seladelpar) receives Health Canada approval for the treatment of primary biliary cholangitis

October 21, 2025

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

October 18, 2025

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

October 18, 2025

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

October 14, 2025

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

October 12, 2025

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

October 8, 2025

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

September 29, 2025

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

September 29, 2025

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

September 24, 2025

Gilead Sciences Commits to Veeva Vault CRM

September 10, 2025

WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.

September 8, 2025

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

September 3, 2025

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

September 3, 2025

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

September 2, 2025

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

August 25, 2025

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

August 20, 2025

Gilead Sciences Announces Second Quarter 2025 Financial Results

August 6, 2025

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention

July 24, 2025

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 23, 2025

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025

July 13, 2025

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

July 8, 2025

Northwell Health named to TIME100 Most Influential Companies 2025 list

June 26, 2025

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

June 24, 2025

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

June 17, 2025

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

May 31, 2025

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

May 30, 2025

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

May 22, 2025

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

May 14, 2025

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

May 6, 2025

Older news releases →

Calls in 2025

Decks in 2025